Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression.
about
Gastrin activates autophagy and increases migration and survival of gastric adenocarcinoma cellsCisplatin inhibits MEK1/2.Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysisSynergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells.Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.
P2860
Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Sorafenib reverses resistance ...... wn-regulating MDR1 expression.
@en
type
label
Sorafenib reverses resistance ...... wn-regulating MDR1 expression.
@en
prefLabel
Sorafenib reverses resistance ...... wn-regulating MDR1 expression.
@en
P2093
P2860
P1433
P1476
Sorafenib reverses resistance ...... wn-regulating MDR1 expression.
@en
P2093
Yi-Sheng Huang
P2860
P2888
P356
10.1007/S12032-014-0470-1
P577
2015-01-13T00:00:00Z
P6179
1002579537